Presentation is loading. Please wait.

Presentation is loading. Please wait.

Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced.

Published byПавел Гавриловић Modified over 5 years ago

Similar presentations

Presentation on theme: "Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced."— Presentation transcript:

1 Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non– Small-Cell Lung Cancer  Massimo Di Maio, MD, Natasha B. Leighl, MD, MMSc, FRCPC, Ciro Gallo, MD, Ronald Feld, MD, Fortunato Ciardiello, MD, PhD, Charles Butts, MD, FRCP, Paolo Maione, MD, Vittorio Gebbia, MD, Floriana Morgillo, MD, PhD, Rafal Wierzbicki, MD, Adolfo Favaretto, MD, Yasmin Alam, MD, MRCP, FRCP, Saverio Cinieri, MD, Salvatore Siena, MD, Roberto Bianco, MD, PhD, Ferdinando Riccardi, MD, Mario Spatafora, MD, Alberto Ravaioli, MD, Raffaella Felletti, MD, Vittorio Fregoni, MD, Giovenzio Genestreti, MD, Antonio Rossi, MD, Gianfranco Mancuso, MD, Morena Fasano, MD, Alessandro Morabito, MD, Ming Sound Tsao, MD, Simona Signoriello, PhD, Francesco Perrone, MD, PhD, Cesare Gridelli, MD  Journal of Thoracic Oncology  Volume 7, Issue 12, Pages (December 2012) DOI: /JTO.0b013e318275b327 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Flow-chart of TORCH study patients for QoL analysis. QoL, Quality of Life. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318275b327) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 A, Rate of patients completing each Quality of Life assessment over the total number of patients entered into the trial B, over the total number completing assessment at baseline and C, over the number of patients without progression or death at each of those time points. Blue bars, cisplatin + gemcitabine; yellow bars, erlotinib. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318275b327) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Box-plot of time distribution of Quality of Life assessments compared with date of randomization, by treatment arm. Line in the box, median value; box hinges, 25th to 75th percentiles; ends of the segments, 10th to 90th percen tiles. Blue boxes: cisplatin/gemcitabine; yellow boxes: erlotinib. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318275b327) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Mean differences in QoL scores. A, QLQ-C30 functioning scales (positive indicate improvement). B, QLQ-C30 symptoms scales (negative indicate improvement). C, QLQ-LC13 symptoms scales (negative indicate improvement). Blue bars, cisplatin/gemcitabine; yellow bars, erlotinib. QoL, Quality of Life. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318275b327) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 Mean differences in selected QoL items in patients with EGFR mutated tumor and in patients with EGFR wild-type tumor. Blue bars, cisplatin/gemcitabine; yellow bars, erlotinib. QoL, Quality of Life; EGFR, epidermal growth factor receptor. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318275b327) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

7 FIGURE 6 Cumulative incidence functions of time-to-deterioration for QoL items. A, QLQ-C30 functioning scales. B, QLQ-C30 symptoms scales. C, QLQ–lung cancer specific module (LC13) symptoms scales. Blue curves, cisplatin/gemcitabine; yellow curves, erlotinib. QoL, Quality of Life. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318275b327) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

8 FIGURE 7 Cumulative incidence functions of time-to-deterioration for selected QoL items in patients with EGFR mutated tumor and in patients with EGFR wild-type tumor. Blue curves, cisplatin/gemcitabine; yellow curves, erlotinib. QoL, Quality of Life; EGFR, epidermal growth factor receptor. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318275b327) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced."

Similar presentations

A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Non-small Cell Lung Cancer Scheduled.

A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Non-small Cell Lung Cancer Scheduled.
Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
Informal Caregiving Burden in Advanced Non-small Cell Lung Cancer: The HABIT study  Cesare Gridelli, MD, Carmine Ferrara, MD, Ciro Guerriero, MD, Salvatore.

Informal Caregiving Burden in Advanced Non-small Cell Lung Cancer: The HABIT study  Cesare Gridelli, MD, Carmine Ferrara, MD, Ciro Guerriero, MD, Salvatore.
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in.

Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in.
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Non-small Cell Lung Cancer Scheduled.

A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Non-small Cell Lung Cancer Scheduled.
Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer  David R. Gandara, MD,

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer  David R. Gandara, MD,
Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib.

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib.
Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients.

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients.
Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step.

Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step.
Informal Caregiving Burden in Advanced Non-small Cell Lung Cancer: The HABIT study  Cesare Gridelli, MD, Carmine Ferrara, MD, Ciro Guerriero, MD, Salvatore.

Informal Caregiving Burden in Advanced Non-small Cell Lung Cancer: The HABIT study  Cesare Gridelli, MD, Carmine Ferrara, MD, Ciro Guerriero, MD, Salvatore.
A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with.

A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with.
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 

Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 
A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium 

A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium 

Similar presentations

Ads by Google